Shanghai Fudan Forward S&T Co

Shanghai Fudan Forward S&T Co PEG

The PEG Ratio (Price/Earnings-to-Growth) of Shanghai Fudan Forward S&T Co (600624.SS) as of Oct 30, 2026 is 0.30. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 0.38 — a change of -22.92% (lower).

PEG

0.30

YoY

-22.92%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Shanghai Fudan Forward S&T Co is 2019 0.30 . PEG Ratio (Price/Earnings-to-Growth) of Shanghai Fudan Forward S&T Co was 2018 0.38 . It decreases by -22.92% lower compared to the previous year.

The Shanghai Fudan Forward S&T Co PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PEG
Date
PEG
Jan 1, 2014
0.40 CNY
Jan 1, 2015
0.31 CNY
Jan 1, 2016
0.43 CNY
Jan 1, 2017
0.39 CNY
Jan 1, 2018
0.38 CNY
Jan 1, 2019
0.30 CNY
The Shanghai Fudan Forward S&T Co PEG history
YEARPEGYoY
0.30-22.92%
0.38-0.73%
0.39-10.17%
0.43+36.94%
0.31-22.45%
0.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Fudan Forward S&T Co Stock analysis

What does Shanghai Fudan Forward S&T Co do? Shanghai Fudan Forward S&T Co., Ltd. generates revenue through the research, development, production, and sale of pharmaceutical products, including digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, and immune function medications. The company also provides financial insurance software products. Its domestic and overseas markets serve as key sales channels for these pharmaceuticals and software solutions. The firm's product portfolio targets healthcare providers, hospitals, and pharmacies within the pharmaceutical sector. The company's pharmaceutical segment focuses on specialized drug categories such as digestive system and nervous system treatments, alongside antineoplastic and circulatory drugs. Financial insurance software products complement its core pharmaceutical business, offering additional revenue streams. Domestic markets account for a significant portion of sales, while overseas markets expand its global reach. Shanghai Fudan Forward S&T Co., Ltd. leverages its 1,426 full-time employees to support both pharmaceutical and software operations. The firm's product offerings cater to healthcare institutions requiring specialized medications and digital solutions for insurance management. This dual focus allows the company to serve multiple segments within the healthcare and financial technology industries. Shanghai Fudan Forward S&T Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Fudan Forward S&T Co stock

PEG Ratio (Price/Earnings-to-Growth) of Shanghai Fudan Forward S&T Co is 0.30 in 2019.

PEG Ratio (Price/Earnings-to-Growth) of Shanghai Fudan Forward S&T Co changed from 0.38 to 0.30, representing a -22.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Shanghai Fudan Forward S&T Co since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Shanghai Fudan Forward S&T Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Shanghai Fudan Forward S&T Co

All Key Metrics — Shanghai Fudan Forward S&T Co